Objectives: To compare semen parameters between patients with testicular cancer and other malignancies using various cut-off values, and to evaluate the correlation between semen parameters and intracytoplasmic sperm injection outcomes. Methods: We retrospectively investigated semen parameters before cancer treatment in 117 patients with malignancies who cryopreserved sperm at Hirosaki University Hospital between November 1999 and May 2016. We compared semen parameters between patients with testicular cancer and other malignancies (non-testicular cancer), seminoma and non-seminoma, and stage I testicular cancer and stage II/III testicular cancer. The assessment of cut-off values recommended by the World Health Organization and the total motile sperm count was carried out between the testicular cancer and non-testicular cancer groups. The intracytoplasmic sperm injection outcomes in those using preserved sperm were assessed. Results: Of the 111 patients enrolled, 29 (26%) had testicular cancer and 82 (74%) had non-testicular cancer. Patients with testicular cancer showed significantly lower total sperm concentration than non-testicular cancer patients. The cut-off value of total sperm concentration distinguished the patient proportions exceeding the cut-off between patients with testicular cancer (41%) and non-testicular cancer (66%). The comparison between patients with seminoma versus non-seminoma and stage I versus stage II/III testicular cancer presented no significant differences in semen parameters. No correlation between pretreatment semen parameters and intracytoplasmic sperm injection outcomes was observed. Conclusions: Although testicular cancer patients show lower total sperm concentration, intracytoplasmic sperm injection outcomes are acceptable. Further studies on the fertility potential of testicular cancer patients are warranted.
Introduction
In recent decades, the importance of fertility preservation has been increasingly emphasized in young patients with cancer. 1 Sperm cryopreservation and ICSI have been widely used as established methods of ART. 2, 3 TC is one of the leading malignancies in males of reproductive age. 4 Although patients with TC are at higher risk of unfavorable semen parameters than those with other malignancies, the success rates with ARTs in those with TC are reportedly comparable with those with other malignancies. 5 However, it remains unclear which parameters have an impact on outcomes of subsequent ART in cancer patients. To date, several semen parameters that possibly correlate to male fertility have been proposed. For instance, the TMSC has been recently used as a simple semen parameter predicting male fertility, 3, 6, 7 while the WHO recommended various semen parameters with their cut-off values. 8 A former study suggested that TMSC is a more predictive value than the WHO cut-off values for ICSI outcomes. 3 However, sufficient research has not been carried out to assess the correlation between semen parameters before cancer treatment and the ICSI outcomes in patients with TC.
In the present study, we compared various semen parameters before cancer treatment between patients with TC and other malignancies with the suggested cut-off values. In addition, we assessed the correlation between semen parameters that exceeded the cut-off values and ICSI outcomes in patients subsequently using their cryopreserved sperm.
Methods

Design and ethics statement
We carried out the present retrospective study in accordance with the ethical standards of the Declaration of Helsinki and obtained approval from the Ethics Review Board of Hirosaki University School of Medicine (Hirosaki, Japan; authorization number: 2017-042). We obtained verbal informed consent from all enrolled participants, which was recorded in a medical chart. Pursuant to the provisions of the ethics committee and its guidelines in Japan, written consent was waived in exchange for public disclosure of study findings in the case of retrospective and/or observational study using material such as the existing documentation. Furthermore, this consent procedure was approved by the ethics committees at Hirosaki University School of Medicine.
Patient selection
We examined 117 male patients with cancer who underwent sperm cryopreservation at Hirosaki University Hospital between November 1999 and May 2016. Of these, we excluded six patients due to a lack of semen analysis data and enrolled 111 patients with valid semen analyses data in the present study. All patients were stratified into two groups to investigate differences therein: those with TC and those with other malignancies (non-TC).
Sperm cryopreservation
Before cancer treatment, medical oncologists proposed sperm cryopreservation to patients of reproductive age; those hoping for future conception were referred to the Department of Fertility Treatment at our hospital. Then, semen samples were collected through masturbation after an indefinite period of abstinence. Experienced embryologists at the Department of Fertility Treatment carried out semen cryopreservation and analysis following methodologies recommended by the WHO manual. 8, 9 Comparison of patient variables
As patients' background, we compared variables, including age, follow-up period and type of malignancy causing sperm preservation, between the TC and non-TC groups. The evaluated semen analyses comprised the nomenclature (normozoospermia, oligozoospermia, asthenozoospermia, pyospermia and azoospermia) and semen parameters, including semen volume (mL), total sperm concentration (910 6 /mL), total sperm number (910 6 /ejaculate), motile sperm concentration (910 6 /mL), progressive motility (%), total motility (%) and TMSC (910 6 ). We defined the total motility and progressive motility as percentages of motile and progressively motile sperm concentrations from the total sperm concentration. The TMSC signifies the pre-wash TMSC evaluated by multiplying the semen volume by the total sperm concentration and percentage progressive motility.
10 Figure 1 shows the calculation of the TMSC and the WHO reference values. Of note, we also compared these variables between patients with seminoma and non-seminoma to assess the difference by pathological characteristics. In addition, we compared semen parameters in patients with stage I (localized) and stage II or III (positive lymph nodes and/or distant metastasis) to elucidate the impact of disease extent on semen parameters.
Evaluation of semen parameters by various cut-off values
We used the cut-off values proposed by the WHO and the normal value of the TMSC to evaluate the semen parameters in patients with TC in relation to the existing criteria. 8 In the present study, the WHO 2010 cut-off values included were as follows: (i) semen volume ≥1.5 mL; (ii) total sperm concentration ≥15 9 10 6 /mL; (ii) total sperm number ≥39 9 10 6 / ejaculation; (iv) progressive motility ≥32%; and (v) total motility ≥40%. 8 We defined the cut-off value for the TMSC as ≥20 (910 6 ) based on a recent study showing that the patient group with the normal TMSC (≥20 9 10 6 ) had a significantly higher fertilization rate than that in the abnormal TMSC group. 3 Then, we assessed a difference in patient proportions that exceeded each cut-off value between patients with TC and non-TC.
Usage, conception and delivery rates
The Department of Fertility Treatment at our hospital recorded the usage of cryopreserved sperm for the subsequent ICSI. All patients anticipating conception with preserved sperm received fertility treatment after their cancer treatment. In addition, the fertility department recorded patients' history of conception and delivery, and we monitored all patients.
Statistical analysis
We carried out statistical analyses using GraphPad Prism 5.03 (GraphPad Software, San Diego, CA, USA). All categorical variables in the present study are reported as percentages and compared using the Fisher's exact test or the v 2 -test. In contrast, quantitative variables are presented as medians with quartiles 1 and 3 (Q1 and 3). We used the Student's t-test for normal distributions and the Mann-Whitney U-test for non-parametric distributions to assess statistical differences among the groups. P < 0.05 was considered statistically significant.
Results
Patient background
The median age of 111 patients was 29 years (interquartile range 24-34 years), and the median follow-up period after sperm cryopreservation was 7.5 years (interquartile range 3.9-10.6 years). We observed no significant difference in the age and follow-up period between the TC and non-TC groups. Hematological malignancies (58 patients, 52%), including lymphoma (26%) and leukemia (18%), were the most frequent causal diseases for sperm cryopreservation, followed by TC (29 patients, 26%; Table 1 ).
Semen analysis
Of the 111 patients, 89 (80%) presented abnormalities in the nomenclature for semen variables. Among the nomenclatures examined, the frequency of oligozoospermia was significantly higher in the TC group (62%) than that in the non-TC group (35%; P = 0.012). The total sperm concentration was significantly lower in the TC group (12.5 [3.0-34.3] 9 10 6 /mL) compared with the non-TC group (31.0 [8.0-63.0] 9 10 6 / mL; P = 0.028). No significant differences were observed in other semen parameters, including the TMSC, between the TC and non-TC groups (Table 1 10 The WHO 2010 reference values assessed in the present study included those three components for the TMSC calculation and the total sperm number and total motility. 8 *A, the motility is fast-forward progressive; B, the motility is slow progressive. non-seminoma showed no significant differences in patients' background and semen parameters (Table 2) . Also, a comparison between stage I and stage II/III TC patients presented no significant differences in any semen parameters (Fig. 3) .
Proportion of patients who exceeded the cutoff values
We compared the proportion of patients who exceeded each cut-off value between the TC and non-TC groups. Of six cutoff values, only the total sperm concentration ≥15 9 10 6 /mL showed a significant difference in the proportion of patients exceeding the cut-off between the TC (41%) and non-TC (66%) groups (P = 0.028). Although the TMSC ≥20 9 10 6 showed a higher proportion of non-TC patients (48%) exceeding the cut-off than the proportion of patients with TC (31%), we observed no significant difference (P = 0.134; Fig. 4 ).
Usage of preserved sperm and ICSI outcome
Of 111 patients who preserved sperm, eight (7.2%) subsequently used their sperm for ARTs, and ICSI was selected by all patients. In the present study, the usage rates in non-TC and TC groups were 6.1% (five patients) and 10.3% (three patients), respectively. Of eight patients who used their sperm, five (63%) succeeded in conception. Of these five patients, the wives of three patients (60%) conceived (Table 1) . Table 3 presents the list of patients who used their sperm, including which parameters exceeded the cutoff values. Except for one patient who presented nonobstructive azoospermia (patient number 8), all seven patients exceeded the cut-off values in the progressive motility and total motility. Patient number 8 underwent an onco-TESE from normal testicular tissue in the resected testis, which will be described in the Discussion. Notably, patients with successful conception or delivery did not present common characteristics regarding the parameters over the cut-off values (Table 3) . 
Discussion
The past decades have highlighted the importance of fertility preservation in patients with cancer, and sperm cryopreservation is currently the only established method of male fertility preservation. However, data of fertility preservation in patients with TC remain insufficient. Furthermore, it is challenging for clinicians to anticipate when the patients will recover normal spermatogenesis after cancer treatment due to the diverse duration of gonadotoxic effects according to treatment regimens; 11 thus, clinicians often need to estimate patients' original fertility at the time before cancer treatment.
Consequently, we compared semen parameters before cancer treatment between patients with TC and other malignancies, and applied various recommended cut-off values that have previously been reported to be correlated with male fertility potential. The results showed that the total sperm concentration was the most distinct parameter between patients with TC and other malignancies. Notably, none of the semen parameters seemingly affected the outcomes of the subsequent ICSI in the present study.
The present results showed that patients with TC exhibited significantly lower total sperm concentration than patients with other malignancies, which is consistent with several mL; (iii) total sperm number ≥39 9 10 6 / ejaculation; (iv) progressive motility ≥32%; and (v) total motility ≥40%. The cut-off value of TMSC was the normal value of ≥20 (910 6 ). 3, 8 Only the total sperm concentration showed a significant difference in the patient proportion exceeding the cut-off between the non-TC and TC groups (P = 0.028).
previous studies. 12, 13 As a reason for the unfavorable semen feature in TC patients, the hypothesis of "testicular dysgenesis syndrome" has been proposed.
14 This concept describes a single underlying entity that includes inferior semen quality, an undescended testis, hypospadias and TC. Indeed, it has been reported that TC and male infertility often coexist and are interrelated factors based on the results from large-scale cohort studies. 15, 16 Interestingly, the present study showed that the sperm motility in patients with TC was not inferior to that in patients with other malignancies. This result is consistent with several studies showing that total motility in patients with TC was higher than the normal value of >40%. 8, 12, 13, 17 However, it remains unclear in the previous literature whether the sperm motility in TC patients is unfavorable. 12, 13, 18, 19 In the present study, we used various cut-off values to evaluate semen parameters in patients with cancer in relation to objective criteria, which has not been previously investigated. As a result, we found that the definition of inferior semen quality was not consistent depending on which cutoff value is used. For instance, although 90% of the TC patients exceeded the cut-off for semen volume, just 41% exceeded the cut-off for total sperm concentration (Fig. 4) . This inconsistency implied the difficulty to inclusively evaluate semen quality in TC patients with a single WHO cutoff. Therefore, the present study assessed a more comprehensive parameter, TMSC, which includes both progressive motility of sperm and the semen volume per ejaculate. A study of 518 patients undergoing ICSI attempts reported that male infertile patients with TMSC ≥20 9 10 6 showed a higher fertilization rate and lower miscarriage rate than those with abnormal TMSC. 3 However, the present study did not observe a significant difference in TMSC between patients with TC and other malignancies, possibly implying that patients with TC and non-TC have a comparable level of fertility potential by ICSI.
We also investigated differences in semen parameters by histopathological characteristics (seminoma vs non-seminoma) and disease extent (stage I vs stage II/III), which previously have not been sufficiently reported. 17, 20, 21 The present results showing no significant differences in both comparisons were not fully consistent with the previous studies. A prospective study compared 37 and 63 patients with seminoma and nonseminoma, respectively, reporting that the concentration of motile and morphologically normal sperm (9.5 vs 2.1 9 10 6 ; P = 0.022) was the only different sperm parameter. 17 In addition, a retrospective study including 1158 patients with TC suggested that those with stage III TC presented significantly lower sperm concentration and sperm number. 20 Conversely to these studies, the present results might imply that the impact of histopathological characteristics and disease extent is limited in patients with TC, although the size of our study did not establish a definitive conclusion.
Furthermore, we assessed usage and success rates in subsequent ICSI. In the present study, 10.3% of the TC patients and 6.1% of the non-TC patients used their cryopreserved sperm afterwards, which corroborates with previous studies on the usage rates in patients with TC (6.9-18.1%) 22, 23 and other cancers (3.4-10.3%). [24] [25] [26] The present results showed that two of three (67%) TC patients and three of five (60%) non-TC patients successfully conceived using ICSI, which was also consistent with several studies reporting pregnancy success rates of 31-82% using cryopreserved sperm in patients with TC. 22, 23, 27 Although we attempted to determine the correlation between semen parameter and ICSI outcomes, no outstanding correlation was established (Table 3) . Of note, these results might imply the limited impact of an unfavorable semen parameter, such as the total sperm concentration, on the ICSI success rate in patients with TC.
Of those who used preserved sperm in the present study, one patient with azoospermia underwent an onco-TESE, which has been suggested as an effective method to retrieve motile sperm from the testis in patients with cancer. In this case, the onco-TESE was carried out from his residual single testis with a non-seminomatous germ cell tumor that occurred 5 years after orchiectomy of the contralateral testis. The resection of normal testicular tissue was macroscopically carried out immediately after the orchiectomy. Morphologically normal and motile sperm were successfully retrieved from the thawed TESE samples and used for multiple cycles of ICSI, although conception has not been achieved to date. 28 This case might suggest the clinical implication of onco-TESE for TC patients with azoospermia before cancer treatment.
The present study had several limitations. First, the retrospective study design and inadequate number of patients hindered definitive conclusions regarding semen characteristics in patients with TC. Prospective and multi-institutional studies are warranted to illustrate semen characteristics in patients with TC. Second, a lack of data regarding cancer treatment regimens and post-treatment clinical data, such as semen analysis and serum status, was another limitation. In addition, our data did not include dosage and the number of cycles of chemotherapy, which possibly affected the decision regarding subsequent usage of preserved sperm. Therefore, elucidating the association among therapeutic process, post-treatment clinical data and ICSI outcomes will be an objective in our next study. Third, the limited data in semen analyses prevented the investigation of all parameters suggested in the WHO 2010, especially morphological abnormalities. Perhaps, the percentage of morphologically abnormal sperm is a factor affecting the success rates of natural and assisted conception. 29 Finally, data of socioeconomic and psychological factors and female factors were also limited in the present study. To precisely evaluate the usage and success rates in subsequent ICSI, further variables, including marital history, number of children, history of fertility treatment, occupation and income, psychological status, and female factors, such as wife's age and the number of retrieved oocytes, need to be analyzed. Despites these limitations, the present study highlighted the fertility potential of cryopreserved sperm in patients with TC, and to our knowledge, this is one of the largest studies of fertility preservation in cancer patients in Japan. 24, 30 In conclusion, patients with TC presented significantly lower total sperm concentration than those with other malignancies. Meanwhile, the impact of histopathological characteristics and disease extent on semen parameters was limited in patients with TC. In addition, an evaluation of semen parameters using various cut-off values implied the inaccuracy of inclusively evaluating semen quality in TC patients with a single cut-off value. The ICSI success might not correlate with whether semen parameters exceed the cut-off values. Nevertheless, more extensive studies are required to elucidate the efficacy of fertility preservation in patients with cancer.
Editorial Comment
Editorial Comment from Dr Namekawa to Differences in semen characteristics between patients with testicular cancer and other malignancies using various cut-off values It has already been reported that testicular cancer (TC) patients have poor semen status. In Japan, Kobayashi et al. reported that the mean sperm concentration was significantly lower in TC patients (30.5 9 10 6 /mL) than in other cancer patients (51.2 9 10 6 /mL; P < 0.05) in their dataset (n = 122). 1 In the present study, Hamano et al. re-confirmed that the proportion of patients who exceeded each cut-off value was significantly lower in the TC group (41%) than in the non-TC group (66%; P = 0.028) using the cut-off value recommended by the World Health Organization. 2 In this article, they also reported that there is no correlation between pretreatment semen parameters and intracytoplasmic sperm injection (ICSI) outcomes. However, just three cases underwent ICSI with their cryopreserved semen, and one of the three patients had normal semen parameters at the time of cryopreservation. Thus, it would be premature to conclude that pretreatment semen parameters are not correlated with ICSI outcomes.
Whether cryopreserved semen should be used for ICSI depends on semen status at the time when the patients desire children after treatment. Post-treatment semen parameters correlate to not only pretreatment semen parameters, but also to anticancer therapy. Previous reports clearly showed that highdose cisplatin-based chemotherapy was significantly associated with impaired spermatogenesis. Brydoy et al. reported that sperm counts were significantly more abnormal after high-dose chemotherapy (cisplatin >850 mg) than lower-dose chemotherapy (cisplatin <850 mg) at 11 years after chemotherapy. 3 Namekawa et al. also reported that the time to recover normospermia was shorter in patients who were treated with less than four cycles of chemotherapy than in those treated with four or more cycles of chemotherapy using Japanese data. 4 In the present study, Hamano et al. did not report post-treatment semen parameters and the anticancer treatments in the patients who underwent ICSI. 2 Such information would be useful for identifying patients for whom cryopreservation of sperm should be recommended.
The effect of pretreatment semen status on post-treatment fertility is a very interesting issue. Hamano et al. now focused on the success rate of ICSI using cryopreserved semen, but what about other patients? How many patients succeeded in their attempts to achieve post-treatment paternity? In a previous large-scale study, the 15-year actuarial paternity rate was 85%, even for TC patients who received chemotherapy. 5 However, there is little information about the pretreatment semen parameters in the study. Hamano et al. have an excellent dataset including 117 cancer patients who underwent sperm cryopreservation. I hope that they will examine treatment options for all cases and the paternity rates, and report them in a further study. 
